Araris Biotech Closes $24 Million Financing Round
"Araris continues to make waves in the industry with its pioneering linker technology, enabling fast and precise production of ADCs"
10-Oct-2022 -
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.
The round was co-led by 4BIO Capital and Pureos Bioventures, with participation ...
antibody-drug conjugate
financing